Table 3.
Preoperative baseline and 6 month follow-up measurements
| SAVR | TAVI | |||
|---|---|---|---|---|
| Baseline | 6 months | Baseline | 6 months | |
| Haemodynamics | ||||
| Heart Rate (bpm) | 64 ± 12 | 65 ± 11 | 65 ± 11 | 66 ± 15 |
| Systolic BP (mmHg) | 131 ± 23 | 133 ± 20 | 127 ± 28 | 134 ± 22 |
| Number of Medicationsa | 1.3 ± 0.8 | 1.4 ± 0.8 | 1.2 ± 1.0 | 1.3 ± 1.0 |
| Systemic Arterial Complianceb | 0.88 ± 0.3 | 0.74 ± 0.2* | 0.81 ± 0.3 | 0.71 ± 0.2 |
| Aortic Valve | ||||
| Peak gradient (mmHg)c | 59 ± 20 | 32 ± 18*** | 54 ± 14 | 25 ± 13*** |
| Zva | 3.9 ± 0.9 | 3.5 ± 0.8* | 4.1 ± 1.6 | 3.0 ± 1.1** |
| Left Ventricle | ||||
| Mass Index (g/m2) | 80 ± 25 | 65 ± 16*** | 82 ± 22 | 68 ± 18*** |
| EDVI (ml/m2) | 95 ± 25 | 77 ± 14*** | 95 ± 25 | 86 ± 19* |
| EF (%) | 52 ± 12 | 57 ± 8** | 52 ± 13 | 55 ± 11 |
Abbreviations: EDVI end diastolic volume indexed to body surface area, EF ejection fraction, Zva valvuloarterial impedance
Paired t test to compare baseline and 6 months: *p < 0.05, **p < 0.01, ***p < 0.001
adefined as any of: ACE inhibitor, angiotensin II receptor antagonist, β blocker, spironolactone, doxazosin, hydralazine, amlodipine, felodipine or bendrofluazide
bDerived as stroke volume index / pulse pressure
cDerived from CMR assessment